| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urothelium | 4 | 2020 | 22 | 1.850 |
Why?
|
| Urologic Neoplasms | 3 | 2020 | 18 | 1.810 |
Why?
|
| Cytodiagnosis | 10 | 2022 | 46 | 1.690 |
Why?
|
| Biopsy, Fine-Needle | 10 | 2020 | 63 | 1.570 |
Why?
|
| Carcinoma | 6 | 2020 | 122 | 1.460 |
Why?
|
| Urine | 4 | 2021 | 45 | 1.420 |
Why?
|
| Thyroid Gland | 6 | 2018 | 81 | 1.280 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 506 | 1.060 |
Why?
|
| Pathology, Clinical | 3 | 2014 | 21 | 1.020 |
Why?
|
| Thyroid Neoplasms | 10 | 2021 | 74 | 0.990 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 670 | 0.970 |
Why?
|
| Nuclear Envelope | 4 | 2014 | 49 | 0.940 |
Why?
|
| Adenocarcinoma | 5 | 2020 | 342 | 0.920 |
Why?
|
| Thyroid Nodule | 3 | 2018 | 14 | 0.780 |
Why?
|
| DNA Mutational Analysis | 2 | 2020 | 195 | 0.760 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 313 | 0.750 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2020 | 141 | 0.730 |
Why?
|
| Neoplasms | 5 | 2014 | 1359 | 0.690 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 25 | 0.690 |
Why?
|
| Immunohistochemistry | 6 | 2020 | 893 | 0.690 |
Why?
|
| Colposcopy | 1 | 2020 | 20 | 0.680 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 319 | 0.670 |
Why?
|
| Cervix Uteri | 1 | 2020 | 60 | 0.660 |
Why?
|
| Kidney Pelvis | 1 | 2019 | 13 | 0.630 |
Why?
|
| Pathology, Molecular | 2 | 2016 | 11 | 0.630 |
Why?
|
| Ureter | 1 | 2019 | 37 | 0.620 |
Why?
|
| Thrombin | 1 | 2018 | 22 | 0.600 |
Why?
|
| Mediastinum | 1 | 2018 | 29 | 0.600 |
Why?
|
| Cytological Techniques | 2 | 2018 | 26 | 0.580 |
Why?
|
| Laboratories | 2 | 2016 | 27 | 0.570 |
Why?
|
| Microscopy | 2 | 2020 | 91 | 0.500 |
Why?
|
| Neoplasm Proteins | 2 | 2008 | 281 | 0.490 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 659 | 0.470 |
Why?
|
| Mutation | 6 | 2021 | 2607 | 0.470 |
Why?
|
| Endoscopy | 2 | 2013 | 110 | 0.440 |
Why?
|
| RNA-Binding Proteins | 2 | 2008 | 434 | 0.430 |
Why?
|
| Pathology, Surgical | 2 | 2013 | 12 | 0.420 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 96 | 0.420 |
Why?
|
| Humans | 41 | 2022 | 63281 | 0.420 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 33 | 0.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 166 | 0.410 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 235 | 0.350 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 1146 | 0.320 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2009 | 16 | 0.320 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 13 | 0.280 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2007 | 21 | 0.280 |
Why?
|
| Carcinoma, Papillary | 6 | 2015 | 36 | 0.280 |
Why?
|
| Endometrial Neoplasms | 1 | 2007 | 61 | 0.270 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 111 | 0.260 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 5443 | 0.250 |
Why?
|
| Interphase | 2 | 2013 | 66 | 0.230 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1649 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 341 | 0.230 |
Why?
|
| Biopsy | 2 | 2019 | 444 | 0.220 |
Why?
|
| Female | 18 | 2021 | 32777 | 0.220 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 92 | 0.220 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2004 | 4 | 0.220 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 105 | 0.220 |
Why?
|
| Fluorescent Dyes | 2 | 2018 | 198 | 0.210 |
Why?
|
| Middle Aged | 9 | 2020 | 17541 | 0.210 |
Why?
|
| Models, Biological | 2 | 2010 | 1177 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 663 | 0.210 |
Why?
|
| Cell Nucleolus | 1 | 2004 | 70 | 0.200 |
Why?
|
| Indoles | 2 | 2015 | 110 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2003 | 58 | 0.200 |
Why?
|
| Hematoxylin | 1 | 2022 | 11 | 0.200 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 12 | 0.200 |
Why?
|
| Sulfonamides | 2 | 2015 | 127 | 0.200 |
Why?
|
| Endosonography | 1 | 2022 | 26 | 0.190 |
Why?
|
| Adult | 8 | 2020 | 16774 | 0.190 |
Why?
|
| Aged | 9 | 2021 | 14385 | 0.190 |
Why?
|
| Urinalysis | 2 | 2020 | 38 | 0.190 |
Why?
|
| Papillomavirus Infections | 2 | 2014 | 129 | 0.190 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2021 | 14 | 0.190 |
Why?
|
| Pericytes | 1 | 2021 | 15 | 0.190 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 32 | 0.180 |
Why?
|
| Quinolines | 1 | 2021 | 45 | 0.180 |
Why?
|
| Urinary Bladder | 1 | 2021 | 45 | 0.170 |
Why?
|
| Curettage | 1 | 2020 | 7 | 0.170 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2020 | 8 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2020 | 11 | 0.170 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 42 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 413 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2021 | 51 | 0.160 |
Why?
|
| Male | 11 | 2021 | 29804 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1084 | 0.160 |
Why?
|
| False Negative Reactions | 2 | 2016 | 41 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2011 | 206 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 524 | 0.150 |
Why?
|
| Plasma | 1 | 2018 | 37 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 1 | 2018 | 400 | 0.130 |
Why?
|
| Papanicolaou Test | 2 | 2014 | 43 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2019 | 6624 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2018 | 568 | 0.130 |
Why?
|
| Vaginal Smears | 2 | 2014 | 56 | 0.130 |
Why?
|
| Cell Nucleus | 5 | 2013 | 626 | 0.130 |
Why?
|
| Genes, p16 | 1 | 2015 | 6 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 20 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2019 | 866 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2460 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2015 | 65 | 0.120 |
Why?
|
| Specimen Handling | 2 | 2013 | 62 | 0.120 |
Why?
|
| Laminin | 2 | 2014 | 78 | 0.120 |
Why?
|
| Algorithms | 2 | 2018 | 1001 | 0.110 |
Why?
|
| Genes, erbB-2 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 197 | 0.110 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2014 | 1 | 0.110 |
Why?
|
| Diploidy | 1 | 2014 | 11 | 0.110 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 19 | 0.110 |
Why?
|
| Prognosis | 3 | 2021 | 1750 | 0.110 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2013 | 1 | 0.110 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2013 | 2 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2013 | 29 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 158 | 0.100 |
Why?
|
| United States | 3 | 2016 | 7829 | 0.100 |
Why?
|
| Goiter | 1 | 2013 | 9 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2013 | 56 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2013 | 26 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 158 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 130 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 104 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 384 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 205 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 98 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 311 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 257 | 0.090 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pathology | 1 | 2011 | 12 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2011 | 71 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2013 | 483 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2013 | 376 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2008 | 278 | 0.080 |
Why?
|
| Melanoma | 1 | 2014 | 331 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 453 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2014 | 1348 | 0.080 |
Why?
|
| Cell Polarity | 1 | 2010 | 109 | 0.080 |
Why?
|
| Chromatin | 2 | 2004 | 610 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 771 | 0.080 |
Why?
|
| Cytoplasm | 2 | 2008 | 276 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 130 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 780 | 0.080 |
Why?
|
| Animals | 6 | 2015 | 20631 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 972 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 412 | 0.080 |
Why?
|
| Pancreatitis, Chronic | 1 | 2008 | 19 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 502 | 0.070 |
Why?
|
| Neoplasms, Ductal, Lobular, and Medullary | 1 | 2007 | 3 | 0.070 |
Why?
|
| Paraffin Embedding | 1 | 2007 | 17 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2014 | 1465 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2007 | 136 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2015 | 608 | 0.070 |
Why?
|
| Desmosomes | 1 | 2006 | 7 | 0.060 |
Why?
|
| Hemidesmosomes | 1 | 2006 | 6 | 0.060 |
Why?
|
| Basement Membrane | 1 | 2006 | 25 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2674 | 0.060 |
Why?
|
| Mammary Glands, Human | 1 | 2006 | 56 | 0.060 |
Why?
|
| Breast | 1 | 2007 | 183 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 304 | 0.060 |
Why?
|
| Heterografts | 2 | 2015 | 63 | 0.060 |
Why?
|
| Nuclear Matrix | 1 | 2004 | 28 | 0.060 |
Why?
|
| Gene Expression | 1 | 2007 | 839 | 0.050 |
Why?
|
| Phenotype | 2 | 2006 | 1200 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2004 | 83 | 0.050 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2003 | 3 | 0.050 |
Why?
|
| Microinjections | 1 | 2003 | 69 | 0.050 |
Why?
|
| Genes, ras | 1 | 2003 | 27 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2015 | 525 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 177 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 125 | 0.050 |
Why?
|
| Point Mutation | 1 | 2003 | 166 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2004 | 122 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2015 | 520 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 449 | 0.050 |
Why?
|
| Risk | 2 | 2014 | 377 | 0.050 |
Why?
|
| Mitosis | 1 | 2003 | 215 | 0.050 |
Why?
|
| Ribosomes | 1 | 2004 | 163 | 0.050 |
Why?
|
| Transfection | 2 | 2015 | 692 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 201 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2004 | 1514 | 0.040 |
Why?
|
| Time Factors | 2 | 2004 | 3759 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2152 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 542 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 1199 | 0.040 |
Why?
|
| Mice | 4 | 2015 | 10827 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 47 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 139 | 0.030 |
Why?
|
| Cytoskeleton | 2 | 2006 | 138 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 451 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 297 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 569 | 0.030 |
Why?
|
| Lamins | 1 | 2013 | 5 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 216 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 207 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2007 | 985 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 47 | 0.020 |
Why?
|
| DNA Damage | 1 | 2013 | 280 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 36 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 42 | 0.020 |
Why?
|
| Cell Line | 2 | 2006 | 2037 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 45 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2011 | 141 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 190 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1073 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 319 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2010 | 192 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 301 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 452 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 664 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2180 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 937 | 0.020 |
Why?
|
| Phyllodes Tumor | 1 | 2007 | 5 | 0.020 |
Why?
|
| Papilloma, Intraductal | 1 | 2007 | 6 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 735 | 0.020 |
Why?
|
| Carcinoma, Lobular | 1 | 2007 | 26 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 88 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2007 | 35 | 0.020 |
Why?
|
| Tight Junctions | 1 | 2006 | 20 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2006 | 135 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2566 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2005 | 51 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2006 | 89 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 139 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2004 | 7 | 0.010 |
Why?
|
| Paxillin | 1 | 2004 | 9 | 0.010 |
Why?
|
| Focal Adhesions | 1 | 2004 | 24 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2004 | 32 | 0.010 |
Why?
|
| Cell Death | 1 | 2006 | 284 | 0.010 |
Why?
|
| Cell Size | 1 | 2004 | 41 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 150 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2004 | 165 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 165 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2004 | 207 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 169 | 0.010 |
Why?
|
| Collagen | 1 | 2004 | 123 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 221 | 0.010 |
Why?
|
| PAX8 Transcription Factor | 1 | 2003 | 1 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4683 | 0.010 |
Why?
|
| Paired Box Transcription Factors | 1 | 2003 | 16 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2004 | 220 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2003 | 41 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 201 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 57 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 259 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 671 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2004 | 190 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 293 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2004 | 255 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 860 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 147 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 429 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 314 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1602 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1539 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1617 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 1184 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2006 | 3033 | 0.010 |
Why?
|